Navigation Links
Psylin Neurosciences Commences Development of Compound for Depression
Date:4/20/2009

SAN DIEGO, April 20 /PRNewswire/ -- Psylin Neurosciences Inc., a joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today that it has initiated IND-enabling development of a novel compound, PSN0041, for the treatment of depression.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/LA01157LOGO )

PSN0041, a peptide from Amylin's proprietary polypeptide hormone library, PHORMOL, was identified as having utility in depression after screening it in PsychoGenics' proprietary, drug discovery technologies. Not only has PSN0041 shown effects in multiple preclinical tests of depression, but also in preclinical tests of anxiety. The peptide has several anticipated advantages over current antidepressant medications including cognitive enhancement, weight loss, a lack of sexual side effects, and an enhanced safety and side effect profile. Psylin's primary aim is to advance PSN0041 rapidly through early clinical development.

"The selection of PSN0041 as a clinical candidate for depression is an important milestone for Psylin. We believe that PSN0041 validates the utility of peptides in this therapeutic arena," said Mark Gergen, Co-CEO of Psylin and Senior Vice President, Corporate Development at Amylin. "It also supports Amylin's belief that value can be derived from PHORMOL in areas outside of Amylin's core focus on diabetes and obesity therapies."

"PsychoGenics and Amylin formed Psylin in 2007 and in just two years identified PSN0041. The productivity of the partnership is the direct result of the good working relationship between both companies, the quality of Amylin's PHORMOL library, and the predictive power of PsychoGenics' proprietary, high throughput,
'/>"/>

SOURCE Psylin Neurosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
2. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
3. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
4. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
5. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
6. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
7. Amarin Signs Agreement to Acquire Ester Neurosciences
8. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy ... that it has signed a letter of intent ... has developed and patented a nanotechnology-based development platform ... products that enable rapid on-site collection and testing ... and health issues in an immediate, non-invasive and ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... assessment to be added to the, ... 28 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or "Company") ... on activities as well as an interim progress ... is conducting a human Phase 1b/2a clinical trial ...
... Sigma-Aldrich (Nasdaq: SIAL ) today announced the global ... provides a novel and powerful approach to RNAi screening in ... http://www.sigma.com/esirna ) incorporates a pool of hundreds of ... designed to eliminate the trial and error approach of identifying ...
... Techne Corporation,s (Nasdaq: TECH ) consolidated net ... to $27.6 million or $.74 per diluted share compared with ... ended March 31, 2008. For the nine months ended ... $79.9 million or $2.10 per diluted share compared with $76.3 ...
Cached Biology Technology:Resverlogix Provides Quarterly Update 2Resverlogix Provides Quarterly Update 3Resverlogix Provides Quarterly Update 4Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 2Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 3Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 5Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 6Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009 7
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... clever trick for overcoming sleep deprivation. Sam Ridgway from the ... to send half of their brains to sleep while the ... to be able to remain continually vigilant for sounds for ... colleagues from San Diego and Tel Aviv wonder whether the ...
... May 1, 2009 As people become more educated, studies ... lower in calories but higher in nutrients. They also pay ... of the Journal of the American Dietetic Association , ... and food costs of a sample of 164 adults in ...
... plants are constantly confronted with adverse environmental conditions, lowering ... use specialized signals, called stress hormones, to sense difficult ... Of the various stress hormones, abscisic acid ... last 30 years as the key hormone that helps ...
Cached Biology News:Dolphins maintain round-the-clock visual vigilance 2People of higher socioeconomic status choose better diets -- but pay more per calorie 2Synthetic chemical offers solution for crops facing drought 2Synthetic chemical offers solution for crops facing drought 3
Request Info...
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Biology Products: